ConductScience.org, home
All databases
API referenceFor AI assistants

Trial comparisons

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,541 to 2,560 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Intervention vs Control: Mortality122 of 1,500

152 of 1,489

-2.1 points

-4.2 to -0.0

2,989NCT00307333

Impact of Heart Rate Characteristics Monitoring in Neonates

Intervention vs Control: serious adverse events122 of 1,500

152 of 1,489

-2.1 points

-4.2 to -0.0

2,989NCT00307333

Impact of Heart Rate Characteristics Monitoring in Neonates

Fondaparinux 2.5 mg vs Placebo: serious adverse events10 of 1,499

16 of 1,488

-0.4 points

-1.1 to 0.3

2,987NCT00443053

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Liberal vs Restrictive: Death96 of 1,493

95 of 1,490

0.1 points

-1.7 to 1.8

2,983NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: Composite Septic Outcome or Death295 of 1,493

323 of 1,490

-1.9 points

-4.8 to 1.0

2,983NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: Disability-free Survival165 of 1,493

172 of 1,490

-0.5 points

-2.8 to 1.8

2,983NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: deaths from any cause96 of 1,493

95 of 1,490

0.1 points

-1.7 to 1.8

2,983NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal vs Restrictive: serious adverse events295 of 1,493

323 of 1,490

-1.9 points

-4.8 to 1.0

2,983NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Liberal Group vs Restrictive Group: Number of Participants With Disability-free Survival1,232 of 1,493

1,223 of 1,490

0.4 points

-2.3 to 3.2

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With a Composite of Mortality or Major Septic Complications195 of 1,493

323 of 1,490

-8.6 points

-11.3 to -5.9

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants Undergoing Renal-replacement Therapy4 of 1,493

13 of 1,490

-0.6 points

-1.2 to -0.1

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With Acute Kidney Injury72 of 1,493

124 of 1,490

-3.5 points

-5.3 to -1.7

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With Unplanned Admission to ICU145 of 1,493

161 of 1,490

-1.1 points

-3.3 to 1.1

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With Surgical-site Infection202 of 1,493

245 of 1,490

-2.9 points

-5.5 to -0.4

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Death96 of 1,493

95 of 1,490

0.1 points

-1.7 to 1.8

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With Sepsis129 of 1,493

157 of 1,490

-1.9 points

-4.0 to 0.2

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With Pneumonia57 of 1,493

54 of 1,490

0.2 points

-1.2 to 1.6

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With Anastomotic Leak35 of 1,493

49 of 1,490

-0.9 points

-2.2 to 0.3

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Death18 of 1,493

31 of 1,490

-0.9 points

-1.8 to 0.0

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Liberal Group vs Restrictive Group: Number of Participants With Pulmonary Edema32 of 1,493

20 of 1,490

0.8 points

-0.2 to 1.8

2,983NCT02073162

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=128"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=128

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00307333-db3e3ff7",
        "title": "Intervention vs Control: Mortality",
        "summary": "122 of 1500 against 152 of 1489; risk difference -2.1 points, 95% interval -4.2 to -0.0; NCT00307333, Impact of Heart Rate Characteristics Monitoring in Neonates",
        "record": "/library/comparisons/NCT00307333-db3e3ff7",
        "nct_id": "NCT00307333",
        "kind": "outcome",
        "participants": 2989,
        "risk_difference": {
          "value": -0.020748600850682794,
          "lower": -0.04155719423146188,
          "upper": -0.00003070386832498828
        },
        "group_1": "122 of 1,500",
        "group_2": "152 of 1,489",
        "difference": "-2.1 points",
        "interval": "-4.2 to -0.0",
        "trial_title": "Impact of Heart Rate Characteristics Monitoring in Neonates"
      },
      {
        "id": "NCT00307333-sae",
        "title": "Intervention vs Control: serious adverse events",
        "summary": "122 of 1500 against 152 of 1489; risk difference -2.1 points, 95% interval -4.2 to -0.0; NCT00307333, Impact of Heart Rate Characteristics Monitoring in Neonates",
        "record": "/library/comparisons/NCT00307333-sae",
        "nct_id": "NCT00307333",
        "kind": "serious-adverse-events",
        "participants": 2989,
        "risk_difference": {
          "value": -0.020748600850682794,
          "lower": -0.04155719423146188,
          "upper": -0.00003070386832498828
        },
        "group_1": "122 of 1,500",
        "group_2": "152 of 1,489",
        "difference": "-2.1 points",
        "interval": "-4.2 to -0.0",
        "trial_title": "Impact of Heart Rate Characteristics Monitoring in Neonates"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=129",
  "request_id": "oVsev-EWSZ6VPb_9"
}
Next page

Ask about these results. The first 10 go in the prompt.

Open in ChatGPT , in a new tabOpen in Claude , in a new tab
About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Related databases

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?
API referenceFor AI assistants